Abstract
Background. Basal cell carcinoma (BCC) is the most prevalent skin cancer. Because of its highly vascular characteristic, it is amendable to treatment with pulse dye laser (PDL). The goal of this study is to determine the safety and efficacy of PDL therapy for mostly facial BCCs. Materials and Methods. Sixteen men and thirteen women (29 total) with 39 biopsy-proven BCCs were treated with 1–4 PDL (595 nm) therapies at 2–4-week intervals. The treatment parameters included pulse energy of 15 J/cm 2, pulse length of 3 millisecond, with no dynamic cooling, and 7 mm spot size. The age of the patients was 30–90 years (mean 73 years). Response rates were evaluated by the clinical assessments with mean followup of 11 months. Results. Twenty-four patients with thirty-two tumors reached at least three months followup: 24/32 (75%) tumors with complete resolution (mean 3 treatment sessions); 5/32 (16%) tumors recurred; 3/32 (9%) tumors with incomplete responses after four treatments. Minimal side effects and discomfort were experienced by the patients with PDL therapy. Conclusion. PDL is a safe, tolerable, and moderately effective method of treating various BCCs. The ideal niche and standardized settings for PDL treatment of BCCs are yet to be determined.
Highlights
Basal cell carcinoma (BCC) is the most prevalent skin cancer in the world, and its prevalence is ever increasing
Size, type, and number of tumors, it is the goal of the dermatologist together with the patient to determine the optimal treatment for the BCC
Patients are often diagnosed with multiple BCCs, many of which are in cosmetically important areas, and have other medical comorbidities which may contraindicate surgical treatment modalities
Summary
Basal cell carcinoma (BCC) is the most prevalent skin cancer in the world, and its prevalence is ever increasing. There are numerous options available to treat BCCs including surgical, destructive, laser, X-ray, intralesional chemotherapy, and topical therapies [1, 2] Each of these treatments has its own risks and benefits as well as varying cure rates. Size, type, and number of tumors, it is the goal of the dermatologist together with the patient to determine the optimal treatment for the BCC They carry high rates of efficacy, ablative procedures that treat BCCs can be time-consuming, costly, and can lead to infections and scarring [2]. Nonablative topical treatments, such as chemotherapy and immunomodulators, can be cumbersome and unreliable when used by patient at home. The ideal niche and standardized settings for PDL treatment of BCCs are yet to be determined
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
